Loading clinical trials...
Loading clinical trials...
A Multicenter, Open-label, Single-dose Pharmacokinetic and Safety Evaluation of HORIZANT (Gabapentin Enacarbil Extended-release Tablets) in Adolescents Aged 13 to 17 Years Old With Moderate-to-severe Primary Restless Legs Syndrome
Conditions
Interventions
HORIZANT 300 mg
Locations
4
United States
Stanford Sleep Medicine Center
Redwood City, California, United States
Pacific Research Network
St Louis, Missouri, United States
SleepMed of South Carolina; SleepMed, Inc.
Columbia, South Carolina, United States
Vanderbilt University School of Medicine
Nashville, Tennessee, United States
Start Date
January 1, 2016
Primary Completion Date
July 19, 2017
Completion Date
July 19, 2017
Last Updated
April 12, 2021
NCT07179406
NCT06726785
NCT06747741
NCT07308080
NCT07194291
NCT03053427
Lead Sponsor
XenoPort, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions